<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion â€” Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion</h2>
    <div class="badge">2025-09-08T13:42:00+00:00</div>
    <ul>
      <li>TransUnion&#x27;s 2025 earnings are expected to rise 4.1% year over year.</li>
<li>Halozyme&#x27;s 2025 earnings are expected to jump 46.1% year over year.</li>
<li>Leidos&#x27; 2025 earnings are projected to grow 9.2% on a year-over-year basis.</li>
<li>Its average gain has been a stellar +25% per year.</li>
<li>TRU, presently carrying a Zacks Rank #2, has witnessed a 5% upward revision in broker ratings over the past four weeks.</li>
<li>LDOS, carrying a Zacks Rank #2 at present, has witnessed a 5.6% upward revision in broker ratings over the past four weeks.</li>
<li>HALO, which currently sports a Zacks Rank #1, has witnessed a 9.1% upward revision in broker ratings over the past four weeks.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Zacks.com%20featured%20highlights%20include%20Halozyme%20Therapeutics%2C%20Leidos%20and%20TransUnion%0A%E2%80%A2%20TransUnion%27s%202025%20earnings%20are%20expected%20to%20rise%204.1%25%20year%20over%20year.%0A%E2%80%A2%20Halozyme%27s%202025%20earnings%20are%20expected%20to%20jump%2046.1%25%20year%20over%20year.%0A%E2%80%A2%20Leidos%27%202025%20earnings%20are%20projected%20to%20grow%209.2%25%20on%20a%20year-over-year%20basis.%0A%E2%80%A2%20Its%20average%20gain%20has%20been%20a%20stellar%20%2B25%25%20per%20year.%0A%E2%80%A2%20TRU%2C%20presently%20carrying%20a%20Zacks%20Rank%20%232%2C%20has%20witnessed%20a%205%25%20upward%20revision%20in%20broker%20ratings%20over%20the%20past%20four%20weeks.%0A%E2%80%A2%20LDOS%2C%20carrying%20a%20Zacks%20Rank%20%232%20at%20present%2C%20has%20witnessed%20a%205.6%25%20upward%20revision%20in%20broker%20ratings%20over%20the%20past%20four%20weeks.%0A%E2%80%A2%20HALO%2C%20which%20currently%20sports%20a%20Zacks%20Rank%20%231%2C%20has%20witnessed%20a%209.1%25%20upward%20revision%20in%20broker%20ratings%20over%20the%20past%20four%20weeks.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fzacks-com-featured-highlights-include-halozyme-therapeutics-leidos-and-transunio%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/zacks-com-featured-highlights-halozyme-134200240.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>